SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
ACORDA THERAPEUTICS
(NQNM:ACOR Last Sale: .9 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (ACOR : $.9)
$43,197 million Market Cap at Market Close, July 1, 2022
Employs 174.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
15 Skyline Drive Research Report Earnings Snapshot - Last 10/30/18
Hawthorne, NY 10532 Fact Sheet
Phone: 914-347-4300 Financial Statements
Peer Comparison
Annual Reports

Ron Cohen, Founder/Chmn./CEO, David Lawrence, CFO
Focus on therapies for nervous system related disorders. IPO at $6 February 9, 2006. Raised $33 million, selling 5.5 million shares, 29% of the outstanding. Lead Manager: Banc of America Securities LLC. Secondary at $9.75 October 4, 2006 raised $31.5 million. FDA issued a negative opinion that questioned the safety and effectiveness of the company's multiple sclerosis drug October 9, 2009. FDA panel backed MS drug fampridine October 15, 2009.
Historical Charts    Technical Analysis
No Historical Data available for ACOR

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common ACOR $.9 $.9 0 .0 $.86 $.94 1,702,309 $.86 $.94 47,997,023
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $43,197,321

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex